Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - updated results from an expanded access programme

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [41] Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy - results from Paloma-3.
    Loibl, Sibylle
    Turner, Nicholas C.
    Ro, Jungsil
    Cristofanilli, Massimo
    Iwata, Hiroji
    Im, Seock-Ah
    Masuda, Norikazu
    Loi, Sherene
    Andre, Fabrice
    Harbeck, Nadia
    Verma, Sunil
    Folkerd, Elizabeth
    Theall, Kathy Puyana
    Zhang, Ke
    Bartlett, Cynthia Huang
    Dowsett, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
    Heo, Mi Hwa
    Kim, Hee Kyung
    Lee, Hansang
    Kim, Ji-Yeon
    Ahn, Jin-Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1100 - +
  • [43] Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer
    Parker, LM
    CLINICAL THERAPEUTICS, 2002, 24 : C43 - C57
  • [44] Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
    Verma, S.
    DeMichele, A. M.
    Loi, S.
    Ro, J.
    Colleoni, M.
    Iwata, H.
    Harbeck, N.
    Stearns, V.
    Cristofanilli, M.
    Bartlett, C. Huang
    Schnell, P.
    Zhang, K.
    Thiele, A.
    Turner, N. C.
    Rugo, H. S.
    CANCER RESEARCH, 2016, 76
  • [45] First results from the PACT programme (patient's anastrozole compliance to therapy programme) evaluating the compliance of postmenopausal women with early breast cancer to endocrine adjuvant therapy and the impact of a standardised information service
    Runnebaum, I. B.
    Stickeler, E.
    Baier, B.
    Hadji, P.
    Jackisch, C.
    Harbeck, N.
    Blettner, M.
    Lueck, H.-J.
    Zaun, S.
    Martin, R-R
    Schmitt, D.
    Schulte, H.
    von Fircks, A. Rexrodt
    Haidinger, R.
    Kreienberg, R.
    ONKOLOGIE, 2010, 33 : 29 - 30
  • [46] Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer
    Freedman, Rachel A.
    Winer, Eric P.
    BREAST, 2010, 19 (02): : 69 - 75
  • [47] Adjuvant endocrine therapy for breast cancer: Giving postmenopausal women a voice
    Vandezande, L.
    Reymen, M.
    Raeymaekers, B.
    Heedfeld, I.
    Biebuyck, D.
    Christiaens, M. R.
    Neven, P.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S30 - S30
  • [48] ECONOMIC EVALUATION OF FULVESTRANT 500MG FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER WHO HAVE PROGRESSED ON ENDOCRINE THERAPY
    Polanco, A. C.
    Salazar, A.
    Soto, H.
    Pizarro, M.
    VALUE IN HEALTH, 2014, 17 (03) : A87 - A87
  • [49] Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
    I. Blancas
    M. Fontanillas
    V. Conde
    J. Lao
    E. Martínez
    M. J. Sotelo
    A. Jaen
    J. L. Bayo
    F. Carabantes
    J. J. Illarramendi
    M. M. Gordon
    J. Cruz
    A. García-Palomo
    C. Mendiola
    E. Pérez-Ruiz
    J. S. Bofill
    J. M. Baena-Cañada
    N. M. Jáñez
    G. Esquerdo
    M. Ruiz-Borrego
    Clinical and Translational Oncology, 2018, 20 : 862 - 869
  • [50] Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
    Blancas, I.
    Fontanillas, M.
    Conde, V.
    Lao, J.
    Martinez, E.
    Sotelo, M. J.
    Jaen, A.
    Bayo, J. L.
    Carabantes, F.
    Illarramendi, J. J.
    Gordon, M. M.
    Cruz, J.
    Garcia-Palomo, A.
    Mendiola, C.
    Perez-Ruiz, E.
    Bofill, J. S.
    Baena-Canada, J. M.
    Janez, N. M.
    Esquerdo, G.
    Ruiz-Borrego, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (07): : 862 - 869
12345